ClinicalTrials.gg
CompletedNCT02719769Updated Sep 27, 2017

Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture

An observational study in Bacteremia and Fungemia, sponsored by Accelerate Diagnostics, Inc.. Completed at 14 sites in United States. Per ClinicalTrials.gov, last updated 2017-09-27.

Sponsored by Accelerate Diagnostics, Inc. · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
4,009
Sex
All
01

Study summary

The "Evaluation of Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture Identification \& Antimicrobial Susceptibility Testing" is designed to validate the clinical performance of the Accelerate ID/AST System for positive blood culture identification and susceptibility testing in a clinical setting. The data from this study will be used to support the 510(k) submission for FDA clearance and global registrations of the device intended for in vitro diagnostic use.

Read the detailed description

The clinical study entitled "Evaluation of Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture Identification \& Antimicrobial Susceptibility Testing" is designed to demonstrate the clinical performance of the Accelerate ID/AST System for positive blood culture identification (ID) and antimicrobial susceptibility testing (AST) in a clinical setting compared to reference results. Approximately 3,000 positive blood culture samples (across all Clinical Sites) will be tested on the investigational device and reference methods. Up to 50% of samples enrolled will be comprised of seeded blood cultures prepared from clinical stock isolates. Quality Control testing will be performed each day of testing. The study population is comprised of left-over clinical specimens that are indicated as positive by blood culture monitoring systems utilized by clinical microbiology laboratories. Positive blood culture samples must be tested on the Accelerate ID/AST System within 8 hours of positivity by the blood culture monitoring system. Testing of clinical samples will continue until the required sample size for each target organism and antimicrobial agent, including sufficient on-scale and resistant strains, are tested across all the sites.

02

Conditions studied

  • Bacteremia
  • Fungemia

Browse trials for

Keywords

  • Positive Blood Culture
03

In context

Bacteremia

297 studies on the registry are indexed under Bacteremia; 51 are open to participants now.

This study's enrollment of 4,009 is above the median of 300 across 125 observational studies indexed under Bacteremia.

Browse Bacteremia studies →

Lead sponsor

Accelerate Diagnostics, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Clinical specimens that are indicated as positive by blood culture monitoring systems utilized by clinical microbiology laboratories.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • De-identified positive blood culture specimens (6 mL aliquot)
  • Seeded blood culture specimens (stock) from archived bacterial and yeast isolates

Exclusion criteria

Exclusion Criteria:

  • Sample volume available \< 6 mL
  • Positive Blood Culture sample > 8 hours post-positivity
  • Sample from patient previously enrolled
  • Sample from blood culture media that contain charcoal e.g., BACTAlert FA, FN bottles
  • Samples from Mycobacterial-type blood culture media e.g., BACTEC Myco/F Lytic, BacT/ALERT MP Bottle, VersaTREK Myco
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
4,009 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Comparison Study - ID Performance

    Positive and Negative Percent Agreement with Comparator Method (Vitek2) by Bacterial/Fungal Target

    Time frame: Approximately 9 months (including pre-clinical phase)

Secondary outcomes

  1. Comparison Study - AST Performance

    Essential and Categorical Agreement with CLSI Frozen Reference Method (BMD) by Antimicrobial

    Time frame: Approximately 9 months (including pre-clinical phase)

07

Study locations

14 sites
  • Banner Health- Laboratory Sciences of Arizona
    Gilbert, Arizona 85234, United States
  • Accelerate Diagnostics Inc.
    Tucson, Arizona 85714, United States
  • UCLA Medical Center
    Los Angeles, California 90046, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • MRI Global
    Palm Bay, Florida 32909-2211, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242-1396, United States
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland 21287, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Lab Alliance of Central New York LLC
    Liverpool, New York 13088, United States
  • The Ohio State University
    Columbus, Ohio 43205, United States
  • Geisinger Clinic
    Danville, Pennsylvania 17822, United States
  • med fusion LLC
    Lewisville, Texas 75067, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53276, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02719769
Lead sponsor
Accelerate Diagnostics, Inc.
Responsible party
Sponsor
First posted
Mar 25, 2016
Start date
Jan 2016
Primary completion
May 2016
Completion
Jan 12, 2017
Last update
Sep 27, 2017

Study contacts

Constance Bridges, B.S., MBA
principal investigator · Accelerate Diagnostics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion